Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,012.82 USD

1,012.82
1,071,783

-1.77 (-0.17%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease

by Zacks Equity Research

The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.

Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update

by Zacks Equity Research

Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.

Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.

Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Bayer's (BAYRY) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.

Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More

by Kinjel Shah

Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release.

UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 8.11% and 86.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sheraz Mian headshot

Top Stock Reports for Exxon Mobil, T-Mobile US & Intuitive Surgical

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), T-Mobile US, Inc. (TMUS) and Intuitive Surgical, Inc. (ISRG).

Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPGP

Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales

by Zacks Equity Research

Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022.

Why Regeneron (REGN) Could Beat Earnings Estimates Again

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update

by Zacks Equity Research

Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $747.33, marking a +1.38% move from the previous day.

Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GSEW

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $735.96, moving -0.01% from the previous trading session.

Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.

Neena Mishra headshot

Why Cash Rich Companies, ETFs are Beating the Market

by Neena Mishra

We discuss Cash Cows & Trendpilot ETFs.